The prognosis for plasmacytoma, or multiple myeloma, is dependent on the stage of the disease, how fast the tumor or tumors are growing, the overall health of the individual and how well the patient is responding to treatment, states the Multiple Myeloma Research Foundation. Albumin level testing, lactate dehydrogenase testing, chromosome analysis and gene expression profiling provide information that helps a doctor determine a individual's prognosis.
For instance, higher levels of LDH or lactate dehydrogenase typically indicate that the disease is more extensive, according to the Multiple Myeloma Research Foundation. On the other hand, higher levels of albumin can indicate a better prognosis. A chromosome analysis that shows no abnormalities is also typically an indication of a more favorable prognosis, while the presence of specific abnormalities can indicate a poor prognosis for individuals with multiple myeloma.
The plasma cells found in bone marrow are a vital part of the immune system, explains the American Cancer Society. Lymphocytes, a particular type of cell important to the immune system, are made of up T and B cells. As B cells fight infection, they mature into plasma cells. Plasma cells that mutate and grow too rapidly are referred to as a plasmacytoma. Most often, this type of cancer develops in the bone, but it can affect many areas of the body. A single plasmacytoma is referred to as isolated or solitary plasmacytoma, and more than one plasmacytoma is referred to as multiple myeloma.